{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T23:06:56Z","timestamp":1779059216930,"version":"3.51.4"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Tobacco Prevention Fonds"},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["323530_221860"],"award-info":[{"award-number":["323530_221860"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["P500PM_221961"],"award-info":[{"award-number":["P500PM_221961"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004784","name":"Novartis Stiftung\u00a0f\u00fcr\u00a0Medizinisch-Biologische Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004784","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015075","name":"Janggen-P\u00f6hn-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015075","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Among people living with HIV, there has been a shift of focus from HIV-related health issues to cardiovascular diseases and cancer. For both, tobacco smoking is a major but insufficiently addressed etiological factor. Evidence from randomized trials suggests that nicotine substitute products such as e-cigarettes and nicotine patches can reduce tobacco smoking and its associated health burden. However, most previous smoking cessation trials primarily included people who are motivated to quit smoking and focused on testing a single nicotine substitute product. The effectiveness of offering a menu of nicotine substitute products to tobacco smokers regardless of their willingness to quit smoking (\u201copt-out\u201d approach) is unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      <jats:italic>Reduce tobacco use in people living with HIV in Switzerland<\/jats:italic>\n                      (RETUNE, NCT06789692) is a pragmatic, 1:1 randomized, multicenter, superiority clinical trial using the Trials within Cohorts (TwiCs) design within the Swiss HIV Cohort Study. RETUNE assesses the effectiveness of offering a menu of different nicotine substitute products, namely electronic cigarettes, nicotine pouches, and nicotine patches, versus usual care. Cohort participants are eligible if they smoke more than one tobacco cigarette per day, do not use any of the substitute products, and have signed the randomization consent following the TwiCs design. Participants randomized to the intervention may choose any of the offered substitutes to be used free of charge for 6 months or decline the offer. Overall, we plan to recruit 972 participants. The primary outcome is tobacco abstinence at 6 months measured as participant-reported past 7-day prevalence abstinence. The primary outcome will be assessed in the intention-to-treat set using a logistic regression model adjusted for region, men having sex with men, current drug users, and number of cigarettes per day at baseline. Secondary outcomes are long-term smoking cessation rates and tobacco-associated health outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>RETUNE started recruitment in February 2025 and is currently ongoing. RETUNE using the TwiCs design will clarify the effectiveness of a preference-based opt-out smoking cessation intervention among people living with HIV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      Clinicaltrials.gov NCT06789692. Registered on January 17th, 2025. The manuscript is aligned with the registry.\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT06789692?cond=NCT06789692&amp;rank=1\" ext-link-type=\"uri\">https:\/\/clinicaltrials.gov\/study\/NCT06789692?cond=NCT06789692&amp;rank=1<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-026-09622-6","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T11:05:09Z","timestamp":1775646309000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Offer of a menu of different nicotine substitute products to REduce Tobacco Use iN pEople living with HIV (RETUNE): a protocol for a pragmatic randomized trial within the Swiss HIV Cohort Study"],"prefix":"10.1186","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9856-3500","authenticated-orcid":false,"given":"Christof Manuel","family":"Sch\u00f6nenberger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Speich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elias R.","family":"Zehnder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David Hans-Ulrich","family":"Haerry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen","family":"Cart-Richter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Jackson-Perry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alissa","family":"Hutter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Aggeler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian","family":"Steinmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra E.","family":"Chaudron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Calmy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Cavassini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Braun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph A.","family":"Fux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Abela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Kusejko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huldrych F.","family":"G\u00fcnthard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Nemeth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andri","family":"Rauch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Wandeler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamara","family":"D\u00f6rr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Notter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maja","family":"Weisser Rohacek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Surial","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aur\u00e9lie","family":"Berthet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reto","family":"Auer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcel P.","family":"Stoeckle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niklaus","family":"Labhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9rique","family":"Chammartin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Briel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Amstutz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the Swiss HIV Cohort Study","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"issue":"11","key":"9622_CR1","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1093\/cid\/cir626","volume":"53","author":"B Hasse","year":"2011","unstructured":"Hasse B, Ledergerber B, Furrer H, et al. Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis. 2011;53(11):1130\u20139. https:\/\/doi.org\/10.1093\/cid\/cir626.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"9622_CR2","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1161\/circulationaha.117.033369","volume":"138","author":"ASV Shah","year":"2018","unstructured":"Shah ASV, Stelzle D, Lee KK, et al. Global burden of atherosclerotic cardiovascular disease in people living with HIV: systematic review and meta-analysis. Circulation. 2018;138(11):1100\u201312. https:\/\/doi.org\/10.1161\/circulationaha.117.033369.","journal-title":"Circulation"},{"issue":"8","key":"9622_CR3","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1001\/jamainternmed.2013.3728","volume":"173","author":"MS Freiberg","year":"2013","unstructured":"Freiberg MS, Chang CC, Kuller LH, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013;173(8):614\u201322. https:\/\/doi.org\/10.1001\/jamainternmed.2013.3728.","journal-title":"JAMA Intern Med"},{"issue":"4","key":"9622_CR4","doi-asserted-by":"publisher","first-page":"e279","DOI":"10.1016\/s2352-3018(20)30036-9","volume":"7","author":"K So-Armah","year":"2020","unstructured":"So-Armah K, Benjamin LA, Bloomfield GS, et al. HIV and cardiovascular disease. Lancet HIV. 2020;7(4):e279\u201393. https:\/\/doi.org\/10.1016\/s2352-3018(20)30036-9.","journal-title":"Lancet HIV"},{"issue":"5","key":"9622_CR5","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1093\/cid\/cis933","volume":"56","author":"M Helleberg","year":"2013","unstructured":"Helleberg M, Afzal S, Kronborg G, et al. Mortality attributable to smoking among HIV-1-infected individuals: a nationwide, population-based cohort study. Clin Infect Dis. 2013;56(5):727\u201334. https:\/\/doi.org\/10.1093\/cid\/cis933.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"9622_CR6","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/bjc.2011.558","volume":"106","author":"GM Clifford","year":"2012","unstructured":"Clifford GM, Lise M, Franceschi S, et al. Lung cancer in the Swiss HIV Cohort Study: role of smoking, immunodeficiency and pulmonary infection. Br J Cancer. 2012;106(3):447\u201352. https:\/\/doi.org\/10.1038\/bjc.2011.558.","journal-title":"Br J Cancer"},{"key":"9622_CR7","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae014","author":"MSR Weber","year":"2024","unstructured":"Weber MSR, Duran Ramirez JJ, Hentzien M, et al. Time trends in causes of death in people with human immunodeficiency virus: insights from the Swiss HIV Cohort Study. Clin Infect Dis. 2024. https:\/\/doi.org\/10.1093\/cid\/ciae014.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"9622_CR8","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/j.1468-1293.2012.00996.x","volume":"13","author":"FM Islam","year":"2012","unstructured":"Islam FM, Wu J, Jansson J, Wilson DP. Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis. HIV Med. 2012;13(8):453\u201368. https:\/\/doi.org\/10.1111\/j.1468-1293.2012.00996.x.","journal-title":"HIV Med"},{"issue":"10","key":"9622_CR9","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1001\/jama.2022.15226","volume":"328","author":"MJ Feinstein","year":"2022","unstructured":"Feinstein MJ. HIV, subclinical cardiovascular disease, and clinical progression: insights from immunologic heterogeneity. JAMA. 2022;328(10):931\u20132. https:\/\/doi.org\/10.1001\/jama.2022.15226.","journal-title":"JAMA"},{"issue":"7","key":"9622_CR10","doi-asserted-by":"publisher","first-page":"507","DOI":"10.7326\/m14-2768","volume":"163","author":"MJ Silverberg","year":"2015","unstructured":"Silverberg MJ, Lau B, Achenbach CJ, et al. Cumulative incidence of cancer among persons with HIV in North America: a cohort study. Ann Intern Med. 2015;163(7):507\u201318. https:\/\/doi.org\/10.7326\/m14-2768.","journal-title":"Ann Intern Med"},{"issue":"10","key":"9622_CR11","doi-asserted-by":"publisher","first-page":"e700","DOI":"10.1016\/s2352-3018(22)00219-3","volume":"9","author":"CB Haas","year":"2022","unstructured":"Haas CB, Engels EA, Horner MJ, et al. Trends and risk of lung cancer among people living with HIV in the USA: a population-based registry linkage study. Lancet HIV. 2022;9(10):e700\u20138. https:\/\/doi.org\/10.1016\/s2352-3018(22)00219-3.","journal-title":"Lancet HIV"},{"issue":"21","key":"9622_CR12","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1093\/eurheartj\/eht528","volume":"35","author":"LG Hemkens","year":"2014","unstructured":"Hemkens LG, Bucher HC. HIV infection and cardiovascular disease. Eur Heart J. 2014;35(21):1373\u201381. https:\/\/doi.org\/10.1093\/eurheartj\/eht528.","journal-title":"Eur Heart J"},{"issue":"24","key":"9622_CR13","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMra0809890","volume":"362","author":"NL Benowitz","year":"2010","unstructured":"Benowitz NL. Nicotine addiction. N Engl J Med. 2010;362(24):2295\u2013303. https:\/\/doi.org\/10.1056\/NEJMra0809890.","journal-title":"N Engl J Med"},{"issue":"12","key":"9622_CR14","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1056\/NEJMp1707409","volume":"377","author":"S Gottlieb","year":"2017","unstructured":"Gottlieb S, Zeller M. A nicotine-focused framework for public health. N Engl J Med. 2017;377(12):1111\u20134. https:\/\/doi.org\/10.1056\/NEJMp1707409.","journal-title":"N Engl J Med"},{"issue":"3","key":"9622_CR15","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1001\/jama.2020.23541","volume":"325","author":"CD Patnode","year":"2021","unstructured":"Patnode CD, Henderson JT, Coppola EL, Melnikow J, Durbin S, Thomas RG. Interventions for tobacco cessation in adults, including pregnant persons: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2021;325(3):280\u201398. https:\/\/doi.org\/10.1001\/jama.2020.23541.","journal-title":"JAMA"},{"issue":"5","key":"9622_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000146.pub5","volume":"5","author":"J Hartmann-Boyce","year":"2018","unstructured":"Hartmann-Boyce J, Chepkin SC, Ye W, Bullen C, Lancaster T. Nicotine replacement therapy versus control for smoking cessation. Cochrane Database Syst Rev. 2018;5(5):Cd000146. https:\/\/doi.org\/10.1002\/14651858.CD000146.pub5.","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"9622_CR17","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1001\/jama.2022.0395","volume":"327","author":"NA Rigotti","year":"2022","unstructured":"Rigotti NA, Kruse GR, Livingstone-Banks J, Hartmann-Boyce J. Treatment of tobacco smoking: a review. JAMA. 2022;327(6):566\u201377. https:\/\/doi.org\/10.1001\/jama.2022.0395.","journal-title":"JAMA"},{"issue":"1","key":"9622_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/1940-0640-8-5","volume":"8","author":"AM Barbeau","year":"2013","unstructured":"Barbeau AM, Burda J, Siegel M. Perceived efficacy of e-cigarettes versus nicotine replacement therapy among successful e-cigarette users: a qualitative approach. Addict Sci Clin Pract. 2013;8(1):5. https:\/\/doi.org\/10.1186\/1940-0640-8-5.","journal-title":"Addict Sci Clin Pract"},{"issue":"1","key":"9622_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010216.pub8","volume":"1","author":"N Lindson","year":"2024","unstructured":"Lindson N, Butler AR, McRobbie H, et al. Electronic cigarettes for smoking cessation. Cochrane Database Syst Rev. 2024;1(1):Cd010216. https:\/\/doi.org\/10.1002\/14651858.CD010216.pub8.","journal-title":"Cochrane Database Syst Rev"},{"key":"9622_CR20","first-page":"6","volume-title":"Evidence review of e-cigarettes and heated tobacco products 2018","author":"A McNeill","year":"2018","unstructured":"McNeill A, Brose LS, Calder R, Bauld L, Robson D. Evidence review of e-cigarettes and heated tobacco products 2018. A report commissioned by public health England London: Public Health England; 2018. p. 6."},{"issue":"10","key":"9622_CR21","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1093\/ntr\/ntaa068","volume":"22","author":"E Lunell","year":"2020","unstructured":"Lunell E, Fagerstr\u00f6m K, Hughes J, Pendrill R. Pharmacokinetic comparison of a novel non-tobacco-based nicotine pouch (ZYN) with conventional, tobacco-based Swedish snus and American moist snuff. Nicotine Tob Res. 2020;22(10):1757\u201363. https:\/\/doi.org\/10.1093\/ntr\/ntaa068.","journal-title":"Nicotine Tob Res"},{"issue":"1","key":"9622_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-10544-x","volume":"12","author":"D Azzopardi","year":"2022","unstructured":"Azzopardi D, Ebajemito J, McEwan M, et al. A randomised study to assess the nicotine pharmacokinetics of an oral nicotine pouch and two nicotine replacement therapy products. Sci Rep. 2022;12(1):6949. https:\/\/doi.org\/10.1038\/s41598-022-10544-x.","journal-title":"Sci Rep"},{"key":"9622_CR23","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.0543","author":"S Anderer","year":"2025","unstructured":"Anderer S. FDA authorizes marketing of ZYN nicotine pouch products. JAMA. 2025. https:\/\/doi.org\/10.1001\/jama.2025.0543.","journal-title":"JAMA"},{"issue":"7","key":"9622_CR24","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1808779","volume":"380","author":"P Hajek","year":"2019","unstructured":"Hajek P, Phillips-Waller A, Przulj D, et al. A randomized trial of E-cigarettes versus nicotine-replacement therapy. N Engl J Med. 2019;380(7):629\u201337. https:\/\/doi.org\/10.1056\/NEJMoa1808779.","journal-title":"N Engl J Med"},{"issue":"9905","key":"9622_CR25","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1016\/s0140-6736(13)61842-5","volume":"382","author":"C Bullen","year":"2013","unstructured":"Bullen C, Howe C, Laugesen M, et al. Electronic cigarettes for smoking cessation: a randomised controlled trial. Lancet. 2013;382(9905):1629\u201337. https:\/\/doi.org\/10.1016\/s0140-6736(13)61842-5.","journal-title":"Lancet"},{"issue":"1","key":"9622_CR26","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/s2213-2600(19)30269-3","volume":"8","author":"N Walker","year":"2020","unstructured":"Walker N, Parag V, Verbiest M, Laking G, Laugesen M, Bullen C. Nicotine patches used in combination with e-cigarettes (with and without nicotine) for smoking cessation: a pragmatic, randomised trial. Lancet Respir Med. 2020;8(1):54\u201364. https:\/\/doi.org\/10.1016\/s2213-2600(19)30269-3.","journal-title":"Lancet Respir Med"},{"issue":"18","key":"9622_CR27","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1001\/jama.2020.18889","volume":"324","author":"MJ Eisenberg","year":"2020","unstructured":"Eisenberg MJ, H\u00e9bert-Losier A, Windle SB, et al. Effect of e-cigarettes plus counseling vs counseling alone on smoking cessation: a randomized clinical trial. Jama. 2020;324(18):1844\u201354. https:\/\/doi.org\/10.1001\/jama.2020.18889.","journal-title":"Jama"},{"issue":"7","key":"9622_CR28","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1056\/NEJMoa2308815","volume":"390","author":"R Auer","year":"2024","unstructured":"Auer R, Schoeni A, Humair JP, et al. Electronic nicotine-delivery systems for smoking cessation. N Engl J Med. 2024;390(7):601\u201310. https:\/\/doi.org\/10.1056\/NEJMoa2308815.","journal-title":"N Engl J Med"},{"issue":"3","key":"9622_CR29","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.ypmed.2004.06.011","volume":"40","author":"C Pisinger","year":"2005","unstructured":"Pisinger C, Vestbo J, Borch-Johnsen K, J\u00f8rgensen T. It is possible to help smokers in early motivational stages to quit. The Inter99 study. Prev Med. 2005;40(3):278\u201384. https:\/\/doi.org\/10.1016\/j.ypmed.2004.06.011.","journal-title":"Prev Med"},{"issue":"3","key":"9622_CR30","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1136\/tobaccocontrol-2015-052662","volume":"26","author":"KA Campbell","year":"2017","unstructured":"Campbell KA, Cooper S, Fahy SJ, et al. Opt-out\u2019 referrals after identifying pregnant smokers using exhaled air carbon monoxide: impact on engagement with smoking cessation support. Tob Control. 2017;26(3):300\u20136. https:\/\/doi.org\/10.1136\/tobaccocontrol-2015-052662.","journal-title":"Tob Control"},{"key":"9622_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmedr.2021.101583","volume":"24","author":"I Worni-Schudel","year":"2021","unstructured":"Worni-Schudel I, Tzalis V, Jakob J, et al. Association between self-reported motivation to quit smoking with effectiveness of smoking cessation intervention among patients hospitalized for acute coronary syndromes in Switzerland. Prev Med Rep. 2021;24:101583. https:\/\/doi.org\/10.1016\/j.pmedr.2021.101583.","journal-title":"Prev Med Rep"},{"issue":"4","key":"9622_CR32","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1001\/jamainternmed.2022.7170","volume":"183","author":"KP Richter","year":"2023","unstructured":"Richter KP, Catley D, Gajewski BJ, et al. The effects of opt-out vs opt-in tobacco treatment on engagement, cessation, and costs: a randomized clinical trial. JAMA Intern Med. 2023;183(4):331\u20139. https:\/\/doi.org\/10.1001\/jamainternmed.2022.7170.","journal-title":"JAMA Intern Med"},{"key":"9622_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102142","volume":"63","author":"MJ Carpenter","year":"2023","unstructured":"Carpenter MJ, Wahlquist AE, Dahne J, et al. Effect of unguided e-cigarette provision on uptake, use, and\u00a0smoking cessation among adults who smoke in the USA: a\u00a0naturalistic, randomised, controlled clinical trial. EClinicalMedicine. 2023;102142. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102142.","journal-title":"EClinicalMedicine"},{"issue":"1","key":"9622_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s13722-021-00254-6","volume":"16","author":"M H\u00e9ron","year":"2021","unstructured":"H\u00e9ron M, Le Faou AL, Ibanez G, M\u00e9tadieu B, Melchior M, El-Khoury Lesueur F. Smoking cessation using preference-based tools: a mixed method pilot study of a novel intervention among smokers with low socioeconomic position. Addict Sci Clin Pract. 2021;16(1):43. https:\/\/doi.org\/10.1186\/s13722-021-00254-6.","journal-title":"Addict Sci Clin Pract"},{"issue":"6","key":"9622_CR35","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1111\/j.1360-0443.2011.03419.x","volume":"106","author":"N Walker","year":"2011","unstructured":"Walker N, Howe C, Bullen C, et al. Does improved access and greater choice of nicotine replacement therapy affect smoking cessation success? Findings from a randomized controlled trial. Addiction. 2011;106(6):1176\u201385. https:\/\/doi.org\/10.1111\/j.1360-0443.2011.03419.x.","journal-title":"Addiction"},{"issue":"1","key":"9622_CR36","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/ije\/dyab141","volume":"51","author":"AU Scherrer","year":"2022","unstructured":"Scherrer AU, Traytel A, Braun DL, et al. Cohort profile update: the Swiss HIV Cohort Study (SHCS). Int J Epidemiol. 2022;51(1):33\u201334j. https:\/\/doi.org\/10.1093\/ije\/dyab141.","journal-title":"Int J Epidemiol"},{"key":"9622_CR37","unstructured":"SHCS. 07.12.2022, https:\/\/www.shcs.ch"},{"key":"9622_CR38","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j3453","volume":"358","author":"S Staniszewska","year":"2017","unstructured":"Staniszewska S, Brett J, Simera I, et al. GRIPP2 reporting checklists: tools to improve reporting of patient and public involvement in research. BMJ. 2017;358:j3453. https:\/\/doi.org\/10.1136\/bmj.j3453.","journal-title":"BMJ"},{"key":"9622_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c1066","volume":"340","author":"C Relton","year":"2010","unstructured":"Relton C, Torgerson D, O\u2019Cathain A, Nicholl J. Rethinking pragmatic randomised controlled trials: introducing the \u201ccohort multiple randomised controlled trial\u201d design. BMJ. 2010;340:c1066. https:\/\/doi.org\/10.1136\/bmj.c1066.","journal-title":"BMJ"},{"issue":"3","key":"9622_CR40","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1097\/ede.0000000000000435","volume":"27","author":"DA Young-Afat","year":"2016","unstructured":"Young-Afat DA, Verkooijen HA, van Gils CH, et al. Brief report: staged-informed consent in the cohort multiple randomized controlled trial design. Epidemiology. 2016;27(3):389\u201392. https:\/\/doi.org\/10.1097\/ede.0000000000000435.","journal-title":"Epidemiology"},{"key":"9622_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00770-6","author":"A-W Chan","year":"2025","unstructured":"Chan A-W, Boutron I, Hopewell S, et al. SPIRIT 2025 statement: updated guideline for protocols of randomised trials. Lancet. 2025. https:\/\/doi.org\/10.1016\/S0140-6736(25)00770-6.","journal-title":"Lancet"},{"key":"9622_CR42","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076316","volume":"384","author":"BC Kahan","year":"2024","unstructured":"Kahan BC, Hindley J, Edwards M, Cro S, Morris TP. The estimands framework: a primer on the ICH E9(R1) addendum. BMJ. 2024;384:e076316. https:\/\/doi.org\/10.1136\/bmj-2023-076316.","journal-title":"BMJ"},{"key":"9622_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.gloepi.2024.100163","volume":"8","author":"R Gal","year":"2024","unstructured":"Gal R, Kessels R, Luijken K, et al. Tailored guidance to apply the estimand framework to trials within cohorts (TwiCs) studies. Global Epidemiology. 2024;8:100163. https:\/\/doi.org\/10.1016\/j.gloepi.2024.100163.","journal-title":"Global Epidemiology"},{"issue":"28","key":"9622_CR44","doi-asserted-by":"publisher","first-page":"5285","DOI":"10.1002\/sim.9916","volume":"42","author":"E Coart","year":"2023","unstructured":"Coart E, Bamps P, Quinaux E, et al. Minimization in randomized clinical trials. Stat Med. 2023;42(28):5285\u2013311. https:\/\/doi.org\/10.1002\/sim.9916.","journal-title":"Stat Med"},{"issue":"3","key":"9622_CR45","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/j.1360-0443.2004.00995.x","volume":"100","author":"R West","year":"2005","unstructured":"West R, Hajek P, Stead L, Stapleton J. Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction. 2005;100(3):299\u2013303. https:\/\/doi.org\/10.1111\/j.1360-0443.2004.00995.x.","journal-title":"Addiction"},{"issue":"7","key":"9622_CR46","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1093\/ntr\/ntz110","volume":"22","author":"ME Piper","year":"2020","unstructured":"Piper ME, Bullen C, Krishnan-Sarin S, et al. Defining and measuring abstinence in clinical trials of smoking cessation interventions: an updated review. Nicotine Tob Res. 2020;22(7):1098\u2013106. https:\/\/doi.org\/10.1093\/ntr\/ntz110.","journal-title":"Nicotine Tob Res"},{"issue":"25","key":"9622_CR47","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1093\/eurheartj\/ehab309","volume":"42","author":"group Sw","year":"2021","unstructured":"group Sw, collaboration ECr. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021;42(25):2439\u201354. https:\/\/doi.org\/10.1093\/eurheartj\/ehab309.","journal-title":"Eur Heart J"},{"key":"9622_CR48","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jclinepi.2019.12.015","volume":"120","author":"AM Couwenberg","year":"2020","unstructured":"Couwenberg AM, Burbach JPM, May AM, Berbee M, Intven MPW, Verkooijen HM. The trials within cohorts design facilitated efficient patient enrollment and generalizability in oncology setting. J Clin Epidemiol. 2020;120:33\u20139. https:\/\/doi.org\/10.1016\/j.jclinepi.2019.12.015.","journal-title":"J Clin Epidemiol"},{"key":"9622_CR49","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jclinepi.2019.05.017","volume":"113","author":"R Gal","year":"2019","unstructured":"Gal R, Monninkhof EM, van Gils CH, et al. The trials within cohorts design faced methodological advantages and disadvantages in the exercise oncology setting. J Clin Epidemiol. 2019;113:137\u201346. https:\/\/doi.org\/10.1016\/j.jclinepi.2019.05.017.","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"9622_CR50","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/sim.4431","volume":"31","author":"BC Kahan","year":"2012","unstructured":"Kahan BC, Morris TP. Improper analysis of trials randomised using stratified blocks or minimisation. Stat Med. 2012;31(4):328\u201340. https:\/\/doi.org\/10.1002\/sim.4431.","journal-title":"Stat Med"},{"issue":"5","key":"9622_CR51","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.jclinepi.2003.09.014","volume":"57","author":"AV Hern\u00e1ndez","year":"2004","unstructured":"Hern\u00e1ndez AV, Steyerberg EW, Habbema JD. Covariate adjustment in randomized controlled trials with dichotomous outcomes increases statistical power and reduces sample size requirements. J Clin Epidemiol. 2004;57(5):454\u201360. https:\/\/doi.org\/10.1016\/j.jclinepi.2003.09.014.","journal-title":"J Clin Epidemiol"},{"key":"9622_CR52","unstructured":"Unit MCT. Covariate adjustment in trials Accessed 22.08.2024, https:\/\/www.mrcctu.ucl.ac.uk\/our-research\/methodology\/analysis\/covariate-adjustment-in-trials\/"},{"issue":"32","key":"9622_CR53","doi-asserted-by":"publisher","first-page":"E901","DOI":"10.1503\/cmaj.200077","volume":"192","author":"S Schandelmaier","year":"2020","unstructured":"Schandelmaier S, Briel M, Varadhan R, et al. Development of the instrument to assess the credibility of effect modification analyses (ICEMAN) in randomized controlled trials and meta-analyses. CMAJ. 2020;192(32):E901-e906. https:\/\/doi.org\/10.1503\/cmaj.200077.","journal-title":"CMAJ"},{"key":"9622_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2024.111469","volume":"174","author":"A Amstutz","year":"2024","unstructured":"Amstutz A, Sch\u00f6nenberger CM, Speich B, et al. Characteristics, consent patterns, and challenges of randomized trials using the trials within cohorts (TwiCs) design a scoping review. J Clin Epidemiol. 2024;111469. https:\/\/doi.org\/10.1016\/j.jclinepi.2024.111469.","journal-title":"J Clin Epidemiol"},{"key":"9622_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2025.111973","volume":"188","author":"ER Zehnder","year":"2025","unstructured":"Zehnder ER, Sch\u00f6nenberger CM, H\u00fcllstrung J, et al. Implementing a randomization consent to enable trials within cohorts in the Swiss HIV Cohort Study - a mixed-methods study. J Clin Epidemiol. 2025;188:111973. https:\/\/doi.org\/10.1016\/j.jclinepi.2025.111973.","journal-title":"J Clin Epidemiol"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-026-09622-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09622-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09622-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T22:35:15Z","timestamp":1779057315000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13063-026-09622-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9622"],"URL":"https:\/\/doi.org\/10.1186\/s13063-026-09622-6","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,8]]},"assertion":[{"value":"5 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"RETUNE was approved by the Ethics Committee for Northern and Central Switzerland (BASEC number 2024\u201302417). The Swiss HIV Cohort Study was approved by the Ethics Committee Zurich (BASEC number 2023\u201302080).Important protocol modifications will be approved by the Ethics committee for Northern and Central Switzerland and communicated by the principal investigators. All new protocol versions will be uploaded on clinicaltrials.gov and on the RETUNE website. A concise protocol amendment history is available on the RETUNE website.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"We have no relationship with any of the product manufacturers or retailers. CMS received a travel grant from Gilead Science for another project not related to this work. BS and MB received unrestricted grants from Moderna (2021\/22) for the conduct of the COVERALL-2 and COVERALL-3 study (unrelated to this project). BS has received honoraria from Moderna and Roche for presenting study results not related to this work. H. F. G. has received grants from the Swiss National Science Foundation, Swiss HIV Cohort Study, Yvonne Jacob Foundation, NIH, Gilead Sciences, ViiV and Roche; and is a subcontractor to a Bill and Melinda Gates Foundation grant (all money to institution), personal fees from Merck, Gilead Sciences, ViiV, Janssen, GSK, Johnson & Johnson, and Novartis for consultancy or data and safety monitoring board membership. All authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"372"}}